Nuvectis Pharma, Inc. (NASDAQ:NVCT – Get Rating) CEO Ron Bentsur purchased 12,245 shares of the stock in a transaction dated Thursday, May 12th. The stock was acquired at an average cost of $16.99 per share, for a total transaction of $208,042.55. Following the completion of the transaction, the chief executive officer now owns 2,957,704 shares of the company’s stock, valued at approximately $50,251,390.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Ron Bentsur also recently made the following trade(s):
- On Monday, March 28th, Ron Bentsur bought 4,000 shares of Nuvectis Pharma stock. The stock was bought at an average price of $7.05 per share, with a total value of $28,200.00.
- On Thursday, March 17th, Ron Bentsur bought 7,000 shares of Nuvectis Pharma stock. The stock was bought at an average price of $7.63 per share, with a total value of $53,410.00.
- On Monday, February 14th, Ron Bentsur bought 8,000 shares of Nuvectis Pharma stock. The stock was bought at an average price of $5.88 per share, with a total value of $47,040.00.
Shares of NVCT opened at $18.85 on Friday. Nuvectis Pharma, Inc. has a 12 month low of $3.08 and a 12 month high of $19.97. The business’s 50-day simple moving average is $9.78.
A hedge fund recently bought a new stake in Nuvectis Pharma stock. BlackRock Inc. purchased a new position in shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT – Get Rating) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 7,872 shares of the company’s stock, valued at approximately $59,000. BlackRock Inc. owned 0.06% of Nuvectis Pharma as of its most recent SEC filing.
About Nuvectis Pharma (Get Rating)
Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases.
- Get a free copy of the StockNews.com research report on Nuvectis Pharma (NVCT)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.